Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors--good or evil?
Language English Country United States Media electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
17981714
DOI
10.2741/2846
PII: 2846
Knihovny.cz E-resources
- MeSH
- Models, Biological MeSH
- Cell Differentiation MeSH
- Chemokine CXCL12 metabolism MeSH
- Chemokines metabolism MeSH
- Dipeptidyl Peptidase 4 metabolism MeSH
- Glioblastoma metabolism MeSH
- Glioma enzymology metabolism MeSH
- Humans MeSH
- Brain metabolism MeSH
- Brain Neoplasms enzymology metabolism MeSH
- Peptide Hydrolases metabolism MeSH
- Receptors, CXCR4 metabolism MeSH
- Gene Expression Regulation, Enzymologic MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Chemokine CXCL12 MeSH
- Chemokines MeSH
- Dipeptidyl Peptidase 4 MeSH
- Peptide Hydrolases MeSH
- Receptors, CXCR4 MeSH
Dipeptidyl peptidase-IV (DPP-IV) represents a unique proteolytic activity cleaving N-terminal X-Pro dipeptides. In addition to canonical DPP-IV/CD26, a number of other molecules have been discovered which exhibit DPP-IV-like enzymatic activity and various degree of structural similarity. These comprise enzymatically active fibroblast activation protein-alpha, DPP-II, DPP8, DPP9 and enzymatically inactive DPP6 and DPP10 that have been grouped as "DPP-IV activity and/or structure homologues" (DASH). Because the enzymatically active DASH can share similar sets of biologically active substrates and are frequently coexpressed within single cell or on tissue level, it is tempting to consider their participation on biological function(s) previously attributed to DPP-IV/CD26. It is speculated that disrupted expression and enzymatic activity of some DASH might corrupt the message carried by their substrates, with consequent promotion of abnormal cell behavior. Thus, modulation of activity of a particular enzyme using e.g. inhibitors, specific antibodies or modifying its expression may be an attractive therapeutic concept in cancer treatment. This review summarizes current knowledge of the expression and possible function of DPP-IV enzymatic activity bearing molecules in human brain tumors.
References provided by Crossref.org